Novo Nordisk Eyes Social Inequality To Enhance Access To Wegovy: 'Have To Be More Intentional'

The CEO of Novo Nordisk NVO, Lars Fruergaard Jorgensen, announced on Friday that the company plans to collaborate with European healthcare systems. The aim is to improve access to its weight-loss drug, Wegovy, for less fortunate and more obese individuals, according to Reuters.

“We can see that the demand for the medicine is so strong, that we actually have to be more intentional in how we actually get through to the patients we would like to get through to and how we collaborate with healthcare systems,” Jorgensen said.

Jorgensen stated at a Reuters Newsmaker event, “In Europe, we would aim to seek reimbursement for those patients with the highest BMI, have co-morbidities, and perhaps also those less fortunate from a socio-economic point of view.”

The Denmark-based company’s injectable Wegovy is a leading product in a new class of highly effective weight-loss drugs. When used alongside dietary and exercise changes, Wegovy leads to an average weight loss of around 15%. Another injectable drug from Novo Nordisk, Ozempic, is becoming a popular choice among celebrities as a ‘miracle’ weightloss drug.

Read Next: These Three New Markets May Propel Novo Nordisk’s Ozempic To Greater Heights

Image Via Shutterstock